Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes.

Farcet, Maria R; Lackner, Cornelia; Antoine, Gerhard; Rabel, Philip O; Wieser, Andreas; Flicker, Andreas; Unger, Ulrike; Modrof, Jens; Kreil, Thomas R

Farcet, Maria R; Lackner, Cornelia; Antoine, Gerhard; Rabel, Philip O; Wieser, Andreas; Flicker, Andreas; Unger, Ulrike; Modrof, Jens; Kreil, Thomas R.

Affiliation

Farcet MR; Global Pathogen Safety, Baxalta (previously Baxter BioScience), Vienna, Austria.
Lackner C; Global Pathogen Safety, Baxalta (previously Baxter BioScience), Vienna, Austria.
Antoine G; Global Pathogen Safety, Baxalta (previously Baxter BioScience), Vienna, Austria.
Rabel PO; Global Pathogen Safety, Baxalta (previously Baxter BioScience), Vienna, Austria.
Wieser A; Global Pathogen Safety, Baxalta (previously Baxter BioScience), Vienna, Austria.
Flicker A; Global Pathogen Safety, Baxalta (previously Baxter BioScience), Vienna, Austria.
Unger U; Global Pathogen Safety, Baxalta (previously Baxter BioScience), Vienna, Austria.
Modrof J; Global Pathogen Safety, Baxalta (previously Baxter BioScience), Vienna, Austria.
Kreil TR; Global Pathogen Safety, Baxalta (previously Baxter BioScience), Vienna, Austria.

Transfusion ; 56(2): 383-91, 2016 Feb.

Article de En | MEDLINE | ID: mdl-26399175

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Plasma sanguin / Virus de l'hépatite E / Inactivation virale / Sécurité transfusionnelle Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Transfusion Année: 2016 Type de document: Article Pays d'affiliation: Autriche

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google